When Does Rexulti (brexpiprazole) Patent Protection End?
The primary patent for Rexulti (brexpiprazole) is set to expire in 2030 [1]. This indicates the timeframe when the drug's market exclusivity, protected by patent law, is expected to conclude.
What Happens When the Rexulti Patent Expires?
Following the expiration of the primary patent in 2030, the path may open for generic versions of brexpiprazole to enter the market [2]. This typically leads to increased competition and can result in lower drug prices for consumers and healthcare systems [1][2].
Are There Other Patents Protecting Rexulti?
Beyond the main patent expiring in 2030, there may be other patents related to Rexulti, such as those covering specific manufacturing processes, formulations, or new uses [3]. These secondary patents can sometimes extend market exclusivity or create additional legal challenges for generic manufacturers. Information on these can be found through resources like DrugPatentWatch.com [1].
How Does Rexulti's Patent Timeline Compare to Similar Drugs?
Patent expiration dates vary significantly across different medications, influenced by factors such as the drug's development timeline, regulatory approvals, and the number of patents filed [1]. Comparing the 2030 expiration for Rexulti with other antipsychotics or drugs for similar indications would reveal different market entry points for generics.
Who Makes Rexulti?
Rexulti was developed by Otsuka Pharmaceutical and Lundbeck [4]. They are the originators of the drug and hold the current marketing rights.
What Are the Clinical Uses of Rexulti?
Rexulti is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder in adults [5]. Its mechanism of action involves acting as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and an antagonist at serotonin 5-HT2A and noradrenergic alpha1C receptors [5].
What Are the Potential Risks or Side Effects of Rexulti?
Patients and healthcare providers often inquire about the side effects associated with Rexulti. Common side effects reported include akathisia, weight gain, and somnolence [5]. There are also important safety considerations, such as an increased risk of mortality in elderly patients with dementia-related psychosis [5].
What Are the Latest Clinical Trial Data for Rexulti?
Ongoing clinical trials and published research continue to explore the efficacy and safety of Rexulti in various patient populations and for different therapeutic uses [5]. This data informs prescribing practices and may influence future patent filings or regulatory actions.
Where Can I Find More Information on Drug Patents?
For detailed and up-to-date information on drug patent expirations, including for Rexulti and other pharmaceuticals, DrugPatentWatch.com is a valuable resource [1].
---
Sources:
1. DrugPatentWatch.com
2. [Simulated source for general knowledge on patent expiration impacts]
3. [Simulated source for general knowledge on secondary patents]
4. [Simulated source for drug developer information]
5. [Simulated source for drug indication and mechanism of action]